Drug targets for Cancer: PD1

Drug Targets for Cancer: PD1 and Cancer

PD-1 is a member of the immunoglobulin superfamily B7 involved in immunomodulation and expressed on the surface of activated T cells especially on germinal center-associated T cells as well as on TILs. The PD-1 pathway has its main function in developing peripheral tolerance. Activation of PD-1 by the two known ligands PD-L1/PD-L2 provoke a suppression of T-cell receptor signaling. Thereby, these two ligands interact with PD-1 on activated T-cells, which induces the inhibition resulting in the down regulation of the immune response during resolution of an infection, during development of self-tolerance, or within the tumor microenvironment.

Drug Targets for Cancer: PD1 related Products

Drug targets for cancer: PD1 research reagents

Other vital drug targets for cancer likePD1:

Drug Targets for Cancer: PD1 Related Reference

Darb-Esfahani S, Kunze CA, Kulbe H, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016;7(2):1486-1499.

Drug Targets for Cancer: PD1 Related Information

Drug Targets for Cancer